SPECIAL FEATURE REVIEW

γδ T cells in cancer: a small population of lymphocytes with big implications

Mathilde Raverdeau¹, Stephen P Cunningham¹, Cathal Harmon²,³ & Lydia Lynch¹,²,³

¹School of Biochemistry and Immunology, Trinity College Dublin, Dublin, Ireland
²Harvard Medical School, Boston, MA, USA
³Brigham and Women’s Hospital, Boston, MA, USA

Correspondence
L Lynch, School of Biochemistry and Immunology, Trinity College Dublin, Dublin, Ireland.
E-mail: lynchl3@tcd.ie

Received 22 April 2019;
Revised 2 September 2019;
Accepted 2 September 2019
doi: 10.1002/cti2.1080

Clinical & Translational Immunology
2019; 8: e1080

Abstract

γδ T cells are a small population of mostly tissue-resident lymphocytes, with both innate and adaptive properties. These unique features make them particularly attractive candidates for the development of new cellular therapy targeted against tumor development. Nevertheless, γδ T cells may play dual roles in cancer, promoting cancer development on the one hand, while participating in antitumor immunity on the other hand. In mice, γδ T-cell subsets preferentially produce IL-17 or IFN-γ. While antitumor functions of murine γδ T cells can be attributed to IFN-γ⁺ γδ T cells, recent studies have implicated IL-17⁺ γδ T cells in tumor growth and metastasis. However, in humans, IL-17⁺ γδ T cells are rare and most studies have attributed a protective role to γδ T cells against cancer. In this review, we will present the current knowledge and most recent findings on γδ T-cell functions in mouse models of tumor development and human cancers. We will also discuss their potential as cellular immunotherapy against cancer.

Keywords: antitumor immunity, CAR T-cells, DOT cells, immunotherapy, tumor progression, γδ T cells

INTRODUCTION

γδ T cells constitute non-MHC-restricted innate-like T-cell populations, poised to be activated rapidly within seconds to minutes, rather than days, and bridge the innate and adaptive immune systems.¹ Although γδ T cells make up only a minor proportion of the CD3⁺ compartment in the circulation and most tissues, because of their rapid cytokine production following activation, they constitute an important first line of defence against infections and are important players in antitumor defence.²,³ Innate recognition of tumor cells and subsequent activation of γδ T cells are mediated by a range of cellular and molecular determinants, including tumor-derived stress ligands and cytokine signals (Figure 1). Despite their well-documented innate properties, the adaptive features of γδ T cells are also essential in their development and function.⁴–⁶ Unlike αβ T cells, activation of γδ T cells through their TCR is generally thought not to be restricted to presentation of peptide by MHC molecules, although a human γδ T-cell clone capable of recognising melanoma tumor antigens MART-1 and gp100 in a MHC I-restricted fashion was recently generated in an artificial experimental system.⁷ The identification of γδ TCR ligands and the antigen-presenting molecules they recognise remains a long-standing quest, although several
candidates, linked to specific γδ T-cell subsets, have been identified. Among these are non-peptidic phosphorylated metabolites, or phosphoantigens (PAgs), recognised by human Vγ9Vδ2 T cells and expressed not only by pathogens but also by tumor cells (Figure 1). In addition, human and murine γδ T cells are thought to be capable of activation by cytokines, independent of TCR-cognate antigen recognition.

γδ T cells can be found in the circulation and in secondary lymphoid organs, but they are mainly resident in barrier tissues, such as the mucosae and the skin, and in adipose tissue. γδ T cells expressing specific Vγ and Vδ chains are enriched in particular locations within the body as illustrated in Table 1. This suggests that tissue-specific factors trigger clonal selection, possibly as a result of infection, cytokine milieu or endogenous antigens, highlighting how little is known about factors controlling activation and expansion of human γδ T-cell subsets. In mice, it is clear that two functional subsets of γδ T cells can be found, one producing IL-17 and one producing IFN-γ. These two subsets can be functionally defined based on differential surface expression of CD27. CD27 is a member of the TNF receptor family and binds to CD70. CD27 is expressed not only on activated lymphocytes but also on tumor cells. While CD27 is present on murine IFN-γ+ γδ T cells, it is absent on the surface of the IL-17+ γδ T cells. On the contrary, IL-17 γδ T cells preferentially express CCR6 and the transcription factor PLZF, which is considered to confer innate-like properties to lymphocytes. Whereas murine γδ T cells acquire TCR-dependent functional maturity during thymic ontogeny, human γδ thymocytes are functionally immature and instead acquire their effector functions in response to peripheral cytokine signals. Nevertheless, human thymic γδ T cells exhibit de novo expression of type 1 transcription factors T-bet and eomesodermin, reflecting their capacity to rapidly differentiate into cytotoxic effectors producing IFN-γ in response to cytokines IL-2 and IL-15.

Unlike in mice, the γδ T-cell compartment in humans cannot be functionally defined based on differential

Figure 1. γδ T cells express an array of activating receptors for tumor cell recognition. Many of these mechanisms rely on the upregulation of stress ligands by tumor cells, including MICA/B (humans), Rae-1/H-60 (mouse) and ULBPs. γδ T cells also display an NK-like phenotype in their expression of NCRs (NKP30, NKP44 and NKP46), particularly following activation. LFA-1, lymphocyte function-associated antigen 1; NKG2D, natural killer group 2 member D; PLZF, promyelocytic leukaemia zinc finger protein; Rae1, retinoic acid early inducible-1; TCR, T-cell receptor; TRAIL, TNF-related apoptosis-inducing ligand; ULBP, UL16-binding proteins. * denotes expression on some clones only.
expression of CD27 and the functional distinction among the different subsets is less clear. Human γδ T cells can be divided into 3 main subsets based on TCRδ-chain usage, Vδ1, Vδ2 and Vδ3, which does not allow for clear discrimination of their different effector functions. Interestingly, Vδ4⁺, Vδ5⁺ and Vδ6⁺ populations of γδ T cells have also been found in patients with diverse infections, but they remain rare and no commercially available antibodies exist for these subsets.\(^9\) Thus, most of the studies of human γδ T cells have focused on the Vδ1, Vδ2 and Vδ3 subsets. While tissue-resident γδ T cells are mostly Vδ1⁺ (and probably Vδ3⁺, as they are sometimes described as Vδ1⁻ Vδ2⁺), the majority of our current knowledge on the biology of human γδ T cells comes from blood-circulating cells, which are mainly Vδ2⁺ (Table 1). Recent studies concerning the human γδ TCR repertoire have revealed distinct innate and adaptive roles for γδ T-cell subsets, depending on TCRγ- and TCRδ-chain usage. In cord blood, the Vδ1 TCR repertoire is highly diverse and private, but undergoes postnatal clonotypic focusing throughout adulthood,\(^18\) as evidenced by the enrichment of discrete Vδ1⁺ clonotypes during cytomegalovirus (CMV) and human immunodeficiency virus (HIV)\(^19\) infection. Within the Vδ2 subset exist highly clonal adaptive populations expressing a Vγ9 Vδ2⁺ TCR, which undergo differentiation and clonal expansion during acute CMV infection, in contrast to the innate-like Vγ9 Vδ2⁺ TCR with limited recognition kinetics and CD3 diversity.\(^20\) The Vδ2⁺ subset constitutes an heterogeneous population of cells, producing a range of pro-inflammatory cytokines including IFN-γ, IL-17, TNF-α, IL-9, but also IL-10 depending on the setting.\(^21–24\)

While IFN-γ-producing γδ T cells are abundant in peripheral blood, IL-17 production by human γδ T cells is rare at homeostasis. However, significant inflammatory insult such as that seen in some cancers and infections can polarise γδ T cells towards a type 17 phenotype.\(^24,37,39,40\) A recent extensive study sequencing bulk transcriptomes of 18,000 human tumors revealed that, among all leukocytes present in the tumors, γδ T cells were most strongly associated with good prognosis.\(^41\) However, the computational approach used to characterise these cells has since been disputed.\(^40\) There have also been reports of γδ T cells having a potential tumor-promoting role in various human malignancies,\(^37,40,42\) likely attributable to their functional plasticity in various inflammatory microenvironments, although determination of a direct immunosuppressive role for human γδ T cells in situ is difficult. Thus, although γδ T cells may still provide good prognostic and therapeutic value in human cancers, more research is required into understanding the balance between pro- and antitumor effector functions, and how this is regulated in the tumor microenvironment.

### γδ T CELLS IN TUMOR IMMUNE SURVEILLANCE AND ANTITUMOR IMMUNITY

**Antitumor functions of murine γδ T cells**

Initial studies performed in murine models of cancer have found protective roles for γδ T cells

| Subset | Common γδ chain pairings | Anatomical localisation | Context for the production of IFN-γ or IL-17 | Other effector molecules |
|--------|--------------------------|-------------------------|---------------------------------------------|-------------------------|
| Mouse\(^a\) | Vγ1 Vδ6.3/6.4 | Liver, secondary lymphoid organs | IFN-γ – cancer,\(^25\) viral infection\(^26\) | TNF, IL-4\(^27\) |
| Vγ2 | Undefined | Liver, lung (rare) | Undefined | Undefined |
| Vγ4 | Vγ4Vδ4 | Lung, liver, dermis, lamina propria, secondary lymphoid organs | IFN-γ – cancer, IL-17 – skin injur\(^29\) | TNF, IL-22\(^30\) |
| Vγ5 | Vγ5Vδ1 (DETC) | Epidermis | IFN-γ – cancer, TLR signalling,\(^31\) NKG2D ligation\(^31\) | TNF, IL-22\(^32\) |
| Vγ6 | Vγ6Vδ1 | Uterine epithelia, lung | IL-17 – bacterial infection,\(^33\) cancer\(^34\) | IL-22\(^35\), IL-4, IL-10\(^27\) |
| Vγ7 | Vγ7Vδ4/5/6 | Gut epithelia | IFN-γ – bacterial infection\(^27\) | IL-4, IL-10\(^27\) |
| Human | Vδ1 | Undefined | Gut epithelia, liver, dermis | IFN-γ – cancer, IL-17 – colorectal cancer\(^36\) | TNF, IL-10\(^23\) |
| Vδ2 | Vγ9Vδ2 | Peripheral blood | IFN-γ – cancer, phosphoantigen stimulation\(^6\) | TNF, IL-9, IL-10\(^23\) |
| Vδ3 | Undefined | Gut epithelia, liver | IL-17 – bacterial infection\(^24\) | TNF, IL-4\(^28\) |

\(^a\)Heilig and Tonegawa nomenclature.
against tumor growth.\textsuperscript{43,44} Several mechanisms, through which they mediate their antitumor effects, have been described, including not only direct killing of tumor cells mediated by cytolytic proteins or NKG2D-dependent mechanisms, but also indirect effects mediated by their production of IFN-\(\gamma\), as illustrated in Figure 2. In this section, we summarise the current knowledge on the different antitumor functions attributed to murine \(\gamma\delta\) T cells.

Early studies on the protective role of \(\gamma\delta\) T cells in mice have been conducted in murine models of skin cancers, induced chemically or by subcutaneous transfer of melanoma or carcinoma cell lines. In all models, crucial roles for \(\gamma\delta\) T cells in antitumor immunity have been described, and studies have shown a NKG2D-mediated mechanism by tissue-resident V\(\gamma\)5+ dendritic epidermal T cells (DETCs) as a main player in \(\gamma\delta\) T-cell antitumor function.\textsuperscript{43–46} DETCs are dendritic-shaped \(\gamma\delta\) T cells, which express a largely invariant V\(\gamma\)5\(\delta\)\(\delta\)1 TCR, and are considered to be a unique and unusual subset of \(\gamma\delta\) T cells, which restricts the extent of findings on these cells to other populations of \(\gamma\delta\) T cells. DETCs constitute the majority of T cells in the murine epidermis, but \(\gamma\delta\) T cells are far less abundant in human skin, and DETC equivalents are not present in humans, although evidence for antitumor function of skin \(\gamma\delta\) T cells also exists in humans.\textsuperscript{47} Interestingly, in vivo studies of skin cancer performed in \(\gamma\delta\) T-cell-deficient mice (TCR\(\delta\)\(\delta\)/C0/C0 mice) did not allow for discrimination between DETCs and other populations of \(\gamma\delta\) T cells, and might have underestimated the role of dermal V\(\gamma\)4+ \(\gamma\delta\) T cells or other subsets infiltrating the skin.\textsuperscript{43,44} Indeed, TCR\(\delta\)\(\delta\)/C0/C0 mice reconstituted with V\(\gamma\)4+ \(\gamma\delta\) T cells had a restored antitumor response against B16 melanoma cells, which relied on IFN-\(\gamma\) and perforin production.\textsuperscript{45,48,49} Importantly, a protective role for \(\gamma\delta\) T cells in antitumor response in mice has been described in other models of cancer and notably in a spontaneous model of B-cell lymphoma.\textsuperscript{49} While both perforin and IFN-\(\gamma\) induce tumor cell death, IFN-\(\gamma\) additionally promotes the recruitment and activation of other cytotoxic lymphocytes such as Th1 cells, NK cells and cytotoxic CD8\(^+\) T cells (CTLs), while inhibiting the differentiation of Th2, Th17 and Treg cells. IFN-\(\gamma\) also drives a pro-inflammatory phenotype in
macrophages and enhances the antigen presentation capacities of professional APCs.\textsuperscript{50} Interestingly, IFN-\(\gamma\) production by \(\gamma\delta\) T cells also enhances MHC I molecule expression at the surface of B16 melanoma cells, thereby promoting their recognition by CTLs (Figure 2).\textsuperscript{51} A recent study in a mouse model of gastrointestinal stromal tumor describes a protective role for \(\gamma\delta\) T cells mediated through the secretion of GM-CSF. This cytokine promoted the maturation of CD103\(^+\) CD11b\(^-\) dendritic cells, which were associated with infiltration of effector CD8 T cells within the tumor.\textsuperscript{52}

Tumor immune surveillance by activated murine \(\gamma\delta\) T cells has been linked to their surface expression of the C-type lectin receptor NKG2D, ligands for which Rae-1 and H-60 (MICA and MICB in humans) are expressed at the surface of stressed cells.\textsuperscript{43,46} In mice, DETCs together with Langerhans cells (epidermal dendritic cells) and tissue-resident CD8\(^+\) memory T cells form a network integrated within the epidermis.\textsuperscript{53} Upregulation of Rae-1 by epidermal cells induces activation and remodelling of DETCs from dendritic- to round-shaped cells, leading to a reorganisation of the epidermal architecture. Rae-1 upregulation also promotes expression of the activation marker CD69 on the DETCs within the epidermis and the killing of tumor cells through a NKG2D-mediated pathway.\textsuperscript{53,46} While expression of NKG2D ligands in humans is associated with better outcome in several types of cancers, NKG2D ligands are often internalised by tumor cells or secreted as soluble forms during immune evasion, but are promoted following exposure to different factors including chemotherapy.\textsuperscript{54} Interestingly, a recent study by Sheppard and colleagues has identified an unexpected tumor-promoting role for NKG2D in a model of hepatocellular carcinoma. The authors proposed that, while NKG2D has evident antitumor function in early stages of cancer, it could exacerbate the pro-inflammatory microenvironment of the tumor at later stages, leading to tissue damage and enhanced cell proliferation, which promoted tumor progression in the liver environment.\textsuperscript{55} While the authors did not look at the implication of \(\gamma\delta\) T cells in this process, these cells could nevertheless play a role, given their enrichment in the liver and their robust cytokine expression in response to many inflammatory signals.\textsuperscript{56}

The engagement of the \(\gamma\delta\) TCR in tumor recognition and elimination by murine \(\gamma\delta\) T cells is also likely, and this is also true in humans.\textsuperscript{57} Indeed, Girardi \textit{et al.}\textsuperscript{43} showed that incubation of murine DETCs with a \(\gamma\delta\) TCR-blocking antibody resulted in impaired lysis of the PDV tumorigenic keratinocyte cell line. However, Dutta \textit{et al.}\textsuperscript{58} have recently shown that blockade of \(\gamma\delta\) TCR with antibodies can induce apoptosis in those cells, which could account for the decrease in killing capacity observed. Recently, Crawford \textit{et al.}\textsuperscript{59} showed that skin-resident intraepithelial \(\gamma\delta\) T cells also induced a rapid adaptive immune response to chemically induced skin carcinogenesis by promoting class switching and secretion of high levels of protective IgE by B cells, indicating that the impact of \(\gamma\delta\) T cells on other cell types might be broader than expected (Figure 2).

Role of human \(\gamma\delta\) T cells in antitumor immunity

The V\(\alpha\)2\(^\ast\) subset

V\(\alpha\)2\(^+\) \(\gamma\delta\) T cells are the predominant subtype in the blood, accounting for 2–5% of circulating CD3\(^+\) lymphocytes.\textsuperscript{60} These cells express a TCR with preferential pairing of V\(\alpha\)2 and V\(\gamma\)9 chains, and mediate effective antitumor immunity directly through cytotoxicity via perforin and granzymes, or indirectly through IFN-\(\gamma\) and TNF production (Figure 2).\textsuperscript{3} Recognition of tumor cells by V\(\gamma\)9\(^+\)V\(\alpha\)2\(^+\) T cells can occur through a host of cell surface receptors for self and non-self ligands, including TCR recognition of tumor antigen and stress ligand receptors. These include NKG2D, FC\(\gamma\)III (CD16), FasL, TRAIL and DNAM-1 (CD226).\textsuperscript{61–65} V\(\gamma\)9\(^+\)V\(\alpha\)2\(^+\) T cells recognise tumor-derived phosphorylated prenyl metabolites in a TCR-dependent manner, which may accumulate intracellularly as a by-product of dysregulated tumor metabolism (Figure 1). One well-studied PAg, isopentenyl pyrophosphate (IPP), can accumulate in cancer cells as a result of the elevated metabolic flux through the mevalonate pathway of cholesterol biosynthesis.\textsuperscript{21,28,66} These non-peptidic antigens are not presented in the context of classical MHC and are instead presented through a non-polymorphic type I transmembrane protein called butyrophilin 3A1 (BTN3A1). BTN proteins of the immunoglobulin (Ig) superfamily consist of a B30.2 intracellular domain and two extracellular Ig domains.\textsuperscript{67} The mechanism of activation of V\(\gamma\)9\(^+\)V\(\alpha\)2\(^+\) T cells by BTN3A1-bound PAg remains controversial,
although it is thought to be triggered by initial intracellular binding of PAg to a positively charged surface pocket within the intracellular B30.2 domain. The resultant conformational change within BTN3A1 has been proposed to confer recognition by the V$_\gamma$9V$\delta$2 TCR in an ‘inside out’ signalling mechanism whereby surface BTN3A1 is sensitive to the intracellular concentration of prenyl pyrophosphate metabolites. These non-MHC-restricted, innate-like recognition kinetics of V$_\gamma$9V$\delta$2 T cells are an attractive candidate for cancer immunotherapy and have been targeted in clinical settings using aminobisphosphonate drugs. Aminobisphosphonates are clinically approved potent inhibitors of the mevalonate pathway, thereby not only promoting direct antitumor effects but also leading to a build-up in endogenous isoprenoid metabolites. Zoledronate is an aminobisphosphonate drug that directly inhibits farnesyl pyrophosphate synthase (FPPS), an enzymatic mediator of the mevalonate pathway, leading to a build-up in endogenous IPP. This, in combination with mitogenic IL-2, induces activation and proliferation of type 1 cytotoxic effector V$_\gamma$ T cells with antitumor potential producing IFN-\(\gamma\), TNF, perforin and granzymes. Thus far, all clinical trials using V$_\gamma$ T cells as an autologous cellular therapy for cancer have focused on ex vivo or in vivo activation and expansion of V$_\gamma$9V$\delta$2 T cells with aminobisphosphonates, with satisfactory safety profiles observed. This highlights the need for a better understanding of how V$_\gamma$9V$\delta$2 T cells become activated in cancer, how their effector functions are regulated and how this may be exploited for therapeutic gain in cancer immunotherapy.

The V$\delta$1$^+$ subset

V$\delta$1$^+$ T cells are a minor population in the blood but represent the predominant tissue-resident population of V$\gamma$ T cells. These cells are mainly found at mucosal sites such as the dermis and intestinal epithelia where they can comprise 20–50% of the tissue-resident lymphoid compartment. Unlike their V$\delta$2$^+$ counterparts, V$\delta$1$^+$ V$\gamma$ T cells do not often preferentially pair with a specific V$_\gamma$ chain (although clonal expansion can be seen in some organs, which can be different among individuals). V$\delta$1$^+$ V$\gamma$ T cells are not activated by PAgS, but can display an NK-like phenotype in their expression of natural cytotoxicity receptors, (NCRs) NKp30, NKp44 and NKP46, depending on the protocol used to expand them. Although a unique ligand for the V$\delta$1$^+$ TCR has yet to be identified, recent studies have elucidated some cognate TCR recognition properties of V$\delta$1$^+$ T cells. A crystallographic study revealed sequential recognition kinetics of the MHC class I homologue MICA by NKG2D and V$\delta$1$^+$ TCR, thereby providing both TCR and costimulatory signals from the same ligand. Some V$\delta$1$^+$ cell lines have been reported to recognise the lipid antigen \(\alpha\)-galactosylercamide (\(\alpha\)-GalCer) presented by CD1d. Furthermore, V$\delta$1$^+$ TCR-mediated recognition of glycolipids presented in the context of CD1c facilitates target cell lysis, Th1 cytokine production and dendritic cell maturation by V$\delta$1$^+$ T cells (Figure 1). Indeed, as with V$\gamma$ T cells, TCR-mediated recognition of host stress ligands by V$\gamma$ T cells may require costimulatory signals. This is exemplified by the TCR-mediated recognition of endothelial protein C receptor (EPCR) expressed on CMV-infected endothelial cells by a V$\gamma$ T-cell clone bearing a V$_\gamma$4V$\delta$5 TCR, which required CMV-induced upregulation of ICAM-1 by target cells for an optimal response. Similar to V$\delta$2$^+$ cells, V$\delta$1$^+$ V$\gamma$ T cells induce tumor cell death through soluble cytotoxic machinery (perforin, granymes and granulysin) and cytokine secretion (IFN-\(\gamma\) and TNF). The cytolytic function of V$\delta$1$^+$ T cells has been shown for a range of haematological and solid malignancies, including acute lymphoblastic leukaemia (ALL), acute myelogenous leukaemia (AML), B-cell chronic lymphocytic leukaemia (B-CLL), neuroblastoma, melanoma and pancreatic, lung and colorectal cancers (CRC). V$\delta$1$^+$ T cells seem to outclass V$\delta$2$^+$ cells in most in vitro and in several in vivo pre-clinical cancer models in terms of cytotoxicity and durability, which may have important implications in the development of next-generation V$\gamma$-based immunotherapies. One advantage V$\delta$1$^+$ cells may have for use in immunotherapy is their resistance to activation-induced cell death (AICD), which has posed significant problems in clinical trials following chronic stimulation of V$_\gamma$9V$\delta$2$^+$ T cells with aminobisphosphonate drugs. Although the cytotoxic capacity of both V$\delta$1$^+$ and V$_\gamma$9V$\delta$2$^+$ T cells makes them attractive targets for the development of next-generation immunotherapies, a broader understanding of how these effector functions are regulated and how they may be polarised towards a pro-tumor phenotype, and whether, like conventional T cells, they become...
inhibited and exhausted in the tumor microenvironment, is required.

γδ T CELLS AS DRIVERS OF TUMOR GROWTH

Pro-tumor function of murine γδ T cells

Studies performed in mouse models indicate that pro-tumor functions of γδ T cells can be largely attributed to the IL-17+ cells (Figure 2). This is in line with the majority of reports on IL-17 production by other innate and adaptive immune cells, although the impact of IL-17 on tumor growth might depend on the type of cancer studied.87 We and others have found that IL-17+ γδ T cells are enriched not only in a variety of murine solid tumor models induced by implantation of tumorigenic cells, but also in spontaneous models of HPV-related carcinogenesis and breast cancer models, for which they are associated with metastasis.34,88–92 In murine models of ovarian, pancreatic and lung cancers, IL-17-producing γδ T cells in tumors were highly proliferative and displayed an activated phenotype.34,89,93 They induced angiogenesis and the recruitment of neutrophils, generally associated with poor prognosis in cancer.92,93 Indeed, neutrophils secrete different tumor-promoting agents, such as growth factors, metalloproteinases (MMPs), neutrophil elastase (NE) and reactive oxygen species (ROS), which directly enhance tumor growth and invasion, promote angiogenesis and suppress antitumor immune cells. Nevertheless, neutrophils display phenotypical and functional plasticity depending on the tumor microenvironment, and have been found to also contribute to antitumor immune response, notably through antibody-dependent cellular cytotoxicity (ADCC) and recruitment of other immune cells.94 IL-17-producing γδ T cells also promoted the recruitment of immunosuppressive neutrophils and small peritoneal macrophages, which inhibit CTL response and enhance tumor growth.34,88,90,93 In a model of pancreatic ductal adenocarcinoma (PDA), IL-17+ γδ T cells were also directly suppressive of T-cell responses. Here, IL-17+ γδ T cells expressed the checkpoint inhibitors PD-L1 and Galectin-9, both of which prevented the activation of αβ CD4+ and CD8+ T cells, indicating that γδ T cells can directly inhibit adaptive antitumor immunity (Figure 2).89 A direct role of IL-17+ γδ T cells on tumor cell proliferation is also possible as IL-17+ γδ T cells from lung tumors expressed IL-22 and amphiregulin, both of which can directly promote tumor cell proliferation (Figure 2).93 Nevertheless, as IL-17-producing γδ T cells are rarely found in humans at steady state, further studies are needed to fully grasp the relevance of these findings for human cancers.

The tumor microenvironment provides favorable conditions for the enrichment of IL-17-producing γδ T cells, notably through enhanced levels of the cytokines IL-1β, IL-6, IL-23 and IL-7, which favor CD27+ γδ T-cell survival and promote IL-17 expression.34,88,92 Jin et al93 showed that in a spontaneous model of lung adenocarcinoma, tumor development alters the local microbiota, which induces the production of IL-1β and IL-23 by myeloid cells resulting in highly proliferative tissue-resident IL-17+ γδ T cells. Interestingly, the IL-17 production in γδ T cells via IL-1β axis is also described in promoting tumor metastasis in a spontaneous model of breast cancer metastasis.92 Interestingly, IL-1β and IL-6 additionally drive the expression of NOS2, associated with tumor evasion, in pro-tumorigenic γδ T cells.95 IL-17+ γδ T-cell recruitment is supported by tumor chemokine secretion, such as CCL2/MCP-1, a molecular target for anticancer therapy and ligand for CCR2, which is highly expressed on tumor-infiltrating γδ T cells.89,91,96–98 The chemokine receptor CCR6, involved in the trafficking of IL-17+ T cells to tissues at steady state, is also expressed by IL-17+ γδ T cells in the tumor bed of PDA and hepatocellular carcinoma.89,90 Indeed, CCR6 and its ligand CCL20 are associated with tumor progression in models of CRC and pancreatic cancer.99,100 Interestingly, in other models, recruitment of IL-17+ γδ T cells to the subcutaneous B16 melanoma tumors and HPV-induced skin lesions, respectively, is associated with a downregulation of CCR6 expression,91,96 indicating that the environmental setting in which the tumor develops might influence the phenotype of the immune cells recruited.

Intrinsic metabolic pathways are another parameter that may influence the recruitment and survival of γδ T cells within the tumor bed. In fact, as cancer progresses, tumor cells override lymphocytes in competition for nutrients, especially glucose, which is essential for T-cell effector functions. Thus, nutrient availability might favor or limit the survival of particular...
immune cells. Our unpublished work suggests that CD27+ and CD27− γδ T cells have different metabolic requirements, which might partially explain the enrichment of the IL-17− subset over the IFN-γ+ one in the tumor, observed in a number of cancer models. In addition, tumor cells and other cells infiltrating the tumor niche express enzymes and excrete products, which can inhibit normal T-cell metabolism. For instance, in models of hepatocellular carcinoma and peritoneal B16 tumor, tumor-infiltrating IL-17+ Vγ6+ γδ T cells express low amounts of the antioxidant glutathione, which make them highly susceptible to ROS produced by tumor-associated neutrophils.101 These recent insights of the effect of metabolic state of the tumor microenvironment on the promotion of pro- or antitumor immune cells require further investigation.

**Pro-tumor function of human γδ T cells**

One potential caveat of the functional plasticity and innate response kinetics of γδ T cells is their susceptibility to polarisation by a particular inflammatory milieu. Although human γδ T cells rarely produce IL-17, several groups have reported an elevated frequency of IL-17+ γδ T (γδT17) cells in response to a combination of Th17-polarising cytokines IL-1β, IL-6, IL-23 and TGF-β in some disease settings.24,39 Many of these cytokines are elevated in the tumor microenvironment of certain cancers, and indeed, there have been some reports of IL-17-producing γδ T cells having a pro-tumor role in various human malignancies.

The first report of IL-17-producing γδ T cells having a pro-tumorigenic role in humans was reported by Wu et al.37 in patients with CRC. They showed that breach of the gut epithelial barrier by tumor dysplasia induced an influx of commensal microbial products, resulting in the accumulation and activation of IL-23-producing inflammatory dendritic cells. This was sufficient to induce γδT17 polarisation of Vδ1+ intraepithelial lymphocytes, with γδ T cells identified as being the main cellular source of IL-17 in human CRC. Production of IL-8 and GM-CSF by γδ T cells resulted in an influx of immunosuppressive neutrophils, which have well-established pro-tumor roles in an array of cancer types in both humans and mice.

McAllister et al.102 used a murine model of pancreatic intraepithelial neoplasia (PanIN), a histological precursor of PDA, to show that the oncogene Kras can induce the expression of IL-17 receptors on PanIN cells and infiltration of IL-17+ lymphocytes into pancreatic stroma. Within the pancreatic tumor microenvironment exists an abundance of type 17-polarising cytokines such as IL-6 and TGF-β.103 They showed an increase in the frequency of RORγt+ cells in PanIN lesions, primarily produced by Th17 (10% IL-17+) and γδ (50% IL-17+) T cells. It has later shown that human PDA consists of a unique inflammatory infiltrate, with γδ T cells making up to 75% of infiltrating T cells, although Gunderson et al.104 have reported a much lower proportion of γδ T cells in the PDA inflammatory infiltrate (< 5%). Using a transgenic murine model of PDA, they identified a substantial population of γδ T cells, which produced IL-10 and IL-17 and restrained γδ T-cell activation through expression of immune checkpoint ligand PD-L1. Although the role of IL-17 in human pancreatic tumorigenesis remains uncharacterised, ablation of γδ T cells resulted in enhanced ββ T-cell tumor infiltration with superior antitumor effector function in TCRδ−/− mice, perhaps highlighting the need for a better understanding of how γδ T-cell anticancer function is regulated in the tumor microenvironment.

A pathological role has also been described for γδT17 cells in human gallbladder cancer (GBC), with an increased frequency of γδ TCRγδ cells in the blood and TIL of patients with GBC.40 Here, γδT17-derived IL-17 induced expression of vascular endothelial growth factor (VEGF) and other pro-angiogenic factors by GBC cells, facilitating tumor growth and survival. A common feature of the cancer types for which a pro-tumorigenic role of γδ T cells has been described is their resistance to conventional chemotherapeutic treatments and poor 5-year survival rates, exemplifying the need for alternative therapies. With the recent clinical success of immunotherapies such as checkpoint blockade and chimeric antigen receptor (CAR) T cells, an argumentative case can be made for targeting γδ T cells; however, the factors that govern the pro- versus anticancer phenotype in the tumor microenvironment must first be further explored.

**APPLICATIONS OF γδ T CELLS IN IMMUNOTHERAPY**

Immunotherapy is a rapidly expanding and diversifying field of clinical oncology, which has...
shown unprecedented success in the clinic. The emergence of immune checkpoint inhibitors and CAR T-cell technology has revolutionised the treatment of malignancy. However, the efficacy of these treatments is limited, for the most part, to haematological neoplasms and solid tumors with high mutational burdens (e.g. metastatic melanoma and MSI-high colon cancer). While current T-cell-based therapies have shown great success in the clinic, several pitfalls in their use still persist. Checkpoint inhibitors are only effective in a minority of patients, acquired resistance and tumor relapse with resistant clones is an increasingly worrying problem. The time and expense involved in the expansion and conversion of patient cells to CAR T-cell products means there is a limited treatment window available to patients with advanced disease. In some cases, this expansion protocol fails completely, leaving few options for further treatment. Similar to checkpoint therapy, the use of CAR T-cells in solid tumors has proven disappointing. This is believed to be in large part by difficulty in drawing them to the affected tissues. Homing to effected tissues requires the expression of a range of chemokine receptors and adhesion molecules, which are not normally expressed by peripheral blood T cells. Successful elimination of tumors is dependent on the persistence of transferred T cells, which can become exhausted. Conversely, some patients suffer detrimental side effects, such as autoimmune colitis and cytokine release syndrome. These side effects can even result in increased morbidity and mortality. Therefore, an off-the-shelf cellular immunotherapy is an attractive proposition. Innate immune cells, such as γδ T cells and NK cells, appear to have an improved safety profile with minimal off-target effects. Furthermore, since these cells are not MHC-restricted cell products can be prepared from a pool of healthy donors and expanded, reducing the costs and unpredictability associated with rapid expansion of patient-derived products. The innate nature of γδ T cells and their ability to recognise a wide range of tumors makes them potentially excellent candidates for cellular therapy.

A pan-cancer analysis of the TCGA database identified γδ T cells as the strongest immune prognostic available in solid tumors. However, the analysis showed wide variability in the infiltration of tumors by γδ T cells. In addition, the computational algorithm used to deconvolute these tumor microarrays, CIBERSORT, has then shown to inaccurately distinguish γδ T cells from other lymphoid populations. This computational-based identification was later optimised by Tosolini et al., allowing for more accurate assessment of γδ TILs from bulk tumor transcriptomes. Moreover, γδ T cells are diverse and often plastic so identifying the most suitable subset and maintaining this phenotype in vivo remains a challenge to be addressed in coming years. For example, the presence of IL-17-producing γδ T cells in colon cancer has been associated with poor prognosis. Interestingly, though a pan-cancer analysis of the TCGA database identified a combined Th1/Th17 immune signature as the most beneficial for patient survival, this group showed the most pronounced Th17 gene signature but appeared balanced by the presence of a Th1 response. This study requires further dissection to determine the relative contribution of Th1 and Th17 genes to this signature. IL-17 has previously been considered pro-tumorigenic, with many IL-17-mediated diseases eventually leading to malignancy. However, this study indicates that IL-17 in context of a Th1 response may be beneficial, but the source and localisation of IL-17 production cannot be identified in current transcriptomic data sets with reasonable certainty. Therefore, this question may benefit from a new approach, and using single-cell transcriptomic analysis to identify the source of this potentially beneficial IL-17 is worth investigation. Homology between murine and human γδ T-cell subsets is poor and makes translation of murine studies to humans a difficult proposition.

Vδ1+ T cells make up a small proportion of the circulating γδ T-cell population. However, they are highly enriched in mucosal tissues including the skin, gut, lung and liver (Table 1). Residing in tissues, Vδ1+ T cells adapt to lower nutrient availability and decreased oxygen levels, which is similar to the tumor microenvironment. Incubation in hypoxia ex vivo has been shown to enhance γδ T-cell cytotoxicity. However, tumors in hypoxic environments begin to secrete soluble NKG2D ligands, rendering γδ T cells incapable of killing these cells. Having previously homed to target organs, adoptively transferred Vδ1+ T cells should be capable of homing again to a target organ containing a tumor. Furthermore, protocols have been developed that allow the rapid expansion of highly cytotoxic donor Vδ1+ T cells.
immune evasion mechanisms available to tumors. These cells act against a broad range of tumor clones and did not select for resistant strains. It is thought that this is mediated through innate NK receptors in addition to TCR recognition of tumor cells. Vδ1+ T cells express a range of germ-line-encoded receptors, which recognise cellular stress (NKG2D) as well as tumor- and viral-associated antigens (NKP44 and NKP46; Figure 1). This is consistent with previous reports, showing that expanded Vδ1+ T cells possess broad cytotoxic potential in solid tumors, including colon cancer. This provides a unique advantage for T cells over conventional αβ T cells. Their ability to recognise a broad range of tumor signals through NK receptors and their TCR allows them to avoid some of the most potent immune evasion mechanisms available to tumors. However, Vδ1+ T cells have been poorly characterised in solid tumors. Despite their enrichment in specific organs (Table 1), tumors nonetheless develop in these tissues, indicating many tumors are capable of evading recognition by Vδ1+ T cells. γδ T cells may also succumb to inhibition through checkpoint molecules. γδ T cells have been shown to express PD-1 transiently after activation; however, the expression of PD-1 and other immune checkpoints such as CTLA-4, TIM3, LAG3 and TIGIT has been poorly characterised on γδ T cells in human tumors and a combination of these molecules may inhibit TCR and NK-receptor recognition of tumors.

Vδ2+ cells are the majority of circulating γδ T cells in humans, and the vast majority of literature surrounding Vδ2+ T cells has focused on a subset expressing the TCR Vδ9 chain. The transcriptional profile of Vγ9Vδ2+ T cells appears to be an amalgamation of αβ T cells and NK cells, giving them aspects of both cells’ functions. Vγ9Vδ2+ T cells have adaptive features such as a somatic recombination of receptors, memory formation and professional antigen presentation, alongside innate features such as an absence of MHC restriction, recognition of conserved microbial and self-antigens and ability to perform ADCC. A wide range of germ-line-encoded activating receptors are also expressed by Vγ9Vδ2+ T cells, which are essential for their antitumor function, including NKG2D, which recognise MICA/B. Vγ9Vδ2+ T cells have been detected in over 30 solid and hematological malignancies. In this study, Vγ9Vδ2+ T cells were associated with prolonged overall survival in CLL, AML, colon and prostate cancers. Interestingly, Vγ9Vδ2+ T-cell infiltration was independent of γδ T-cell accumulation, indicating that infiltration by γδ T cells is via a different mechanism to conventional αβ T cells. Vγ9Vδ2+ T cells account for about 5% of peripheral blood T cells, so are readily available for in vivo and ex vivo expansion. The drug zoledronate has been used in several clinical trials to promote the in vivo expansion of Vγ9Vδ2+ T cells. While this proved a safe treatment, the efficacy was disappointing and failed to prevent progression in most patients. Ex vivo expansion of γδ T cells using zoledronate and IL-2 has also been trialled in a number of studies, improving disease progression but failing to achieve improved overall survival in a number of solid tumor types (renal cell carcinoma, lung cancer, hepatocellular carcinoma). These early trials should be interpreted with caution as they were designed for assessing safety of γδ T-cell products and not their efficacy. As of March 2019, there are currently 13 active clinical trials (clinicaltrials.gov) involving the use of γδ T cells to treat a broad range of cancers including leukemia and breast, pancreatic, ovarian, liver, kidney, lung and brain cancers. These trials involve combinations of in vivo expansion using drugs such as zoledronate and alendronate, infusions of ex vivo-expanded γδ T cells and surgical interventions such as cryosurgery or irreversible electroporation (NanoKnife; Table 2). However, these trials utilise techniques used in previous trials with low rates of success. Perhaps then, new approaches to γδ T-cell-based immunotherapy are required.

While the current trend in immunotherapy involves the use of checkpoint inhibitors to release the suppression of T cells, this therapy may not drive antitumor responses in innate T cells, such as γδ T cells. As many γδ T cells are not MHC-restricted, the co-inhibitory pathways associated with antigen presentation, such as PD-1 and CTLA-4, may be redundant in their tumor recognition. Therefore, γδ T cells may require release of additional immune checkpoints such as TIGIT, a potent inhibitor of NK cells. The expression of immune checkpoints such as TIGIT, TIM3, LAG3 and NKG2A remains poorly characterised in tumor-infiltrating γδ T cells and may provide synergistic targets to combine with conventional T-cell targets such as PD-1.

Recently, γδ T cells have been incorporated into CAR therapy, producing sufficient cells from Vδ1+
and Vδ2+ subsets for clinical studies.124,125 An additional perquisite of using γδ T cells for immunotherapy lies in their ability to cross-present processed tumor antigen to αβ T cells, and this process is retained in CAR-γδ T cells, further enhancing their antitumor effects.124

**FUTURE DIRECTIONS**

With the advancement of chimeric antigen receptor (CAR) engineering, interest in cellular therapies has increased dramatically. Furthermore, robust expansion protocols for the production of γδ T cells en masse have made their use in the clinic feasible.32,57,114 The safety profile of innate lymphocytes compared to conventional T cells and their lack of MHC restriction makes them an attractive target for off-the-shelf cell therapy. However, further fundamental research is needed to grasp fully the pleiotropic roles of γδ T cells in cancer. In addition, inhibitory pathways used by tumors to evade recognition by γδ T cells have been poorly characterised and warrant further investigation. Additional and more advanced-phase clinical trials are required to determine the efficacy of γδ T-cell-based therapies. γδ T cells are a strong positive prognostic in most cancers. They naturally infiltrate tissues throughout the body, including lung, liver and the gut, some of the most difficult organs in which to treat malignancies. They recognise a broad range of tumors, not only through their TCR but also through NK receptors. Furthermore, they fail to induce graft-versus-host disease and autoimmune complications. This potent effector function, broad range of activity and safety profile make them an ideal potential cellular therapy to enhance current immunotherapy strategies and improve the treatment of solid malignancies.

**ACKNOWLEDGMENTS**

The authors declare no conflict of interest. This work was supported by Science Foundation Ireland Grant (#16/FRL/3865) and European Research Council (ERC) Starting Grant (679173) to LL. Figures were made using modified material from Servier Medical Art. Servier Medical Art by Servier is licensed under a Creative Commons Attribution 3.0 Unported Licence (CC BY 3.0) available at creativecommons.org/licenses/by/3.0/.

**CONFLICT OF INTEREST**

The authors declare no conflict of interest.

**REFERENCES**

1. Fisch P, Malkovsky M, Braakman E, et al. Gamma/delta T cell clones and natural killer cell clones mediate distinct patterns of non-major histocompatibility complex-restricted cytolysis. J Exp Med 1990; 171: 1567–1579.
2. Chitadze G, Oberg HH, Wesch D, et al. The ambiguous role of γδ T lymphocytes in antitumor immunity. Trends Immunol 2017; 38: 668–678.
3. Silva-Santos B, Serre K, Norell H. γδ T cells in cancer. Nat Rev Immunol 2015; 15: 683–691.
4. Munoz-Ruiz M, Sumaria N, Pennington DJ, et al. Thymic determinants of γδ T cell differentiation. Trends Immunol 2017; 38: 336–344.
γδ T cells in cancer

5. Ravens S, Schultze-Florey C, Raha S, et al. Human γδ T cells are quickly reconstituted after stem-cell transplantation and show adaptive clonal expansion in response to viral infection. Nat Immunol 2017; 18: 393–401.

6. Davey MS, Willcox CR, Joyce SP, et al. Clonal selection in the human Vδ1 T cell repertoire indicates γδ TCR-dependent adaptive immune surveillance. Nat Commun 2017; 8: 14760.

7. Benveniste PM, Roy S, Nakatsugawa M, et al. Generation and molecular recognition of melanoma-associated antigen-specific human γδ T cells. Sci Immunol 2018; 3: eaav4036.

8. Willcox BE, Willcox CR. γδ TCR ligands: the quest to solve a 500-million-year-old mystery. Nat Immunol 2019; 20: 121–128.

9. Ribot JC, deBarros A, Pang DJ, et al. CD27 is a thymic determinant of the balance between interferon-γ- and interleukin 17-producing γδ T cell subsets. Nat Immunol 2009; 10: 427–436.

10. Haas JD, Gonzalez FH, Schmitz S, et al. CCR10 and NK1.1 distinguish between IL-17A and IFN-γ-producing γδ effector T cells. Eur J Immunol 2009; 39: 3488–3497.

11. Kohlgruber AC, Gal-Oz ST, LaMarche NM, et al. γδ T cells producing interleukin-17A regulate adipose regulatory T cell homeostasis and thermogenesis. Nat Immunol 2018; 19: 464–474.

12. Lu Y, Cao X, Zhang X, et al. PLZF controls the development of fetal-derived IL-17Vδ2+ γδ T cells. J Immunol 2015; 195: 4273–4281.

13. Kreslavsky T, Savage AK, Hobbs R, et al. TCR-inducible PLZF transcription factor required for innate phenotype of a subset of γδ T cells with restricted TCR diversity. Proc Natl Acad Sci USA 2009; 106: 12453–12458.

14. Haas JD, Ravens S, Duber S, et al. Development of interleukin-17-producing γδ T cells is restricted to a functional embryonic wave. Immunity 2012; 37: 48–59.

15. Ribot JC, Ribeiro ST, Correia DV, et al. Human γδ thymocytes are functionally immature and differentiate into cytotoxic type 1 effector T cells upon IL-2/IL-15 signaling. J Immunol 2014; 192: 2237–2243.

16. Prinz I, Silva-Santos B, Pennington DJ. Functional development of γδ T cells. J Exp Immunol 2013; 43: 1988–1994.

17. Christophoulus P, Bukatz D, Kock S, et al. Improved analysis of TCRgd variable region expression in humans. J Immunol Methods 2016; 434: 66–72.

18. Davey MS, Willcox CR, Joyce SP, et al. Clonal selection in the human Vδ1 T cell repertoire indicates gd TCR-dependent adaptive immune surveillance. Nat Commun 2017; 8: 14670.

19. De Maria A, Ferrazin A, Ferrini S, et al. Selective increase of a subset of T cell receptor γδ T lymphocytes in the peripheral blood of patients with human immunodeficiency virus type 1 infection. J Infect Dis 1992; 165: 917–919.

20. Davey SM, Willcox CR, Hunter S, et al. The human Vδ2+ T-cell compartment comprises distinct innate-like Vγ9+ and adaptive Vγ9- subsets. Nat Commun 2018; 9: 1760.

21. Dunne MR, Mangan BA, Madrigal-Estebas L, et al. Preferential Th1 cytokine profile of phosphoantigen-stimulated human Vγ9Vδ2 T cells. Mediators Inflamm 2010; 2010: 704941.

22. Peters C, Hasler R, Wesch D, et al. Human Vδ2 T cells are a major source of interleukin-9. Proc Natl Acad Sci USA 2016; 113: 12520–12525.

23. Mao Y, Yin S, Zhang J, et al. A new effect of IL-4 on human γδ T cells: promoting regulatory Vδ1 T cells via IL-10 production and inhibiting function of Vδ2 T cells. Cell Mol Immunol 2016; 13: 217–228.

24. Caccamo N, La Mendola C, Orlando V, et al. Differentiation, phenotype, and function of interleukin-17-producing human Vγ9Vδ2 T cells. Blood 2011; 118: 129–138.

25. Hao J, Dong S, Xia S, et al. Regulatory role of Vγ1+ γδ T cells in tumor immunity through IL-4 production. J Immunol 2011; 187: 4979–4986.

26. Chinomori T, Takimoto H, Matsuzaki G, et al. Vγ1+ γδ T cells play protective roles at an early phase of murine cytomegalovirus infection through production of interferon-gamma. Immunology 2000; 99: 187–194.

27. Kohyama M, Nanno M, Kawaguchi-Miyashita M, et al. Cytoytic and IFN-γ-producing activities of γδ T cells in the mouse intestinal epithelium are T cell receptor-β-chain dependent. Proc Natl Acad Sci USA 1999; 96: 7451–7455.

28. Alexander AA, Maniar A, Cummings JS, et al. Isopentenyl pyrophosphosphate-activated CD56+ γδ T lymphocytes display potent antitumor activity toward human squamous cell carcinoma. Clin Cancer Res 2008; 14: 4232–4240.

29. Li Y, Wu J, Luo G, et al. Functions of Vγ4 T cells and dendritic epidermal T cells on skin wound healing. Front Immunol 2018; 9: 1099.

30. Cai Y, Shen X, Ding C, et al. Pivotal role of dermal IL-17-producing γδ T cells in skin inflammation. Immunity 2011; 35: 596–610.

31. Macleod AS, Havran WL. Functions of skin-resident γδ T cells. Cell Mol Life Sci 2011; 68: 2399–2408.

32. Deniger DC, Maiti SN, Mi T, et al. Activating and propagating polyclonal gamma delta T cells with broad specificity for malignancies. Clin Cancer Res 2014; 20: 5708–5719.

33. Marchitto MC, Dillen CA, Liu H, et al. Clonal Vγ6Vδ4+ T cells promote IL-17-mediated immunity against Staphylococcus aureus skin infection. Proc Natl Acad Sci USA 2019; 116: 10917–10926.

34. Mei M, Goncalves-Sousa N, Lanca T, et al. Murine CD27+ Vγ6+ γδ T cells producing IL-17A promote ovarian cancer growth via mobilization of protumor small peritoneal macrophages. Proc Natl Acad Sci USA 2014; 111: E3562–E3570.

35. Simonian PL, Wehrmann F, Roark CL, et al. γδ T cells protect against lung fibrosis via IL-22. J Exp Med 2010; 207: 2239–2253.

36. Halim L, Parente-Pereira AC, Maher J. Prospects for immunotherapy of acute myeloid leukemia using γδ T cells. Immunotherapy 2017; 9: 111–114.

37. Wu P, Wu D, Ni C, et al. γδT17 cells promote the accumulation and expansion of myeloid-derived suppressor cells in human colorectal cancer. Immunity 2014; 40: 785–800.

38. Mangan BA, Dunne MR, O’Reilly VP, et al. Cutting edge: CD1d restriction and Th1/Th2/Th17 cytokine secretion by human Vδ3 T cells. J Immunol 2013; 191: 30–34.
39. Peng MY, Wang ZH, Yao CY, et al. Interleukin 17-producing γδ T cells increased in patients with active pulmonary tuberculosis. Cell Mol Immunol 2008; 5: 203–208.

40. Patil RS, Shah SU, Shrikhande SV, et al. IL17 producing γδ T cells induce angiogenesis and are associated with poor survival in gallbladder cancer patients. Int J Cancer 2016; 139: 869–881.

41. Gentles AJ, Newman AM, Liu CL, et al. Contributions of murine T cell receptor (TCR) γδ+ T cells to different stages of chemically induced skin cancer. J Exp Med 2003; 198: 747–755.

42. Gao Y, Yang W, Pan M, et al. γδ T cells provide an early source of interferon γ in tumor immunity. J Exp Med 2003; 199: 433–442.

43. Strid J, Roberts SJ, Filler RB, et al. Acute upregulation of an NKG2D ligand promotes rapid reorganization of a local immune compartment with pleiotropic effects on carcinogenesis. Nat Immunol 2008; 9: 146–154.

44. Bachelez H, Flageul B, Degos L, et al. TCR γδ bearing T lymphocytes infiltrating human primary cutaneous melanomas. J Invest Dermatol 1992; 98: 369–374.

45. He W, Hao J, Dong S, et al. Naturally activated Vγ4γδ T cells play a protective role in tumor immunity through expression of eomesodermin. J Immunol 2010; 185: 126–133.

46. Street SE, Hayakawa Y, Zhan Y, et al. Innate immune surveillance of spontaneous B cell lymphomas by natural killer cells and γδ T cells. J Exp Med 2004; 199: 879–884.

47. Castro F, Cardoso AP, Goncalves RM, et al. Interferon-γamma at the crossroads of tumor immune surveillance or evasion. Front Immunol 2018; 9: 847.

48. Riond J, Rodriguez S, Nicolau ML, et al. In vivo major histocompatibility complex class I (MHC I) expression on MHC class Ilow tumor cells is regulated by γδ T and NK cells during the early steps of tumor growth. Cancer Immunol 2009; 9: 10.

49. Medina BD, Liu M, Vitiello GA, et al. Oncogenic kinase inhibition limits Baf3-dependent dendritic cell development and antitumor immunity. J Exp Med 2019; 216: 1359–1376.

50. Heath WR, Carbone FR. The skin-resident and migratory immune system in steady state and memory: innate lymphocytes, dendritic cells and T cells. Nat Immunol 2013; 14: 978–985.

51. Hu J, Bernatchez C, Zhang L, et al. Induction of NKG2D ligands on solid tumors requires tumor-specific CDB8 T cells and histone acetyltransferases. Cancer Immunol Res 2017; 5: 300–311.

52. Sheppard S, Guedes J, Mroz A, et al. The immunoreceptor NKG2D promotes tumour growth in a model of hepatocellular carcinoma. Nat Commun 2017; 8: 13930.
73. Salim M, Knowles TJ, Baker AT, et al. BTN3A1 discriminates γδ T cell phosphoantigens from nonantigenic small molecules via a conformational sensor in its B30.2 domain. ACS Chem Biol 2017; 12: 2631–2643.

74. Li J, Herold MJ, Kimmel B, et al. Reduced expression of the mevalonate pathway enzyme farnesyl pyrophosphate synthase unveils recognition of tumor cells by Vγ9Vδ2 T cells. J Immunol 2009; 182: 8118–8124.

75. Kondo M, Sakuta K, Noguchi A, et al. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy. Cytotherapy 2008; 10: 842–856.

76. Benouna J, Bompas E, Neidhardt EM, et al. Phase I study of Innacell γδTM, an autologous cell-therapy product highly enriched in γδ T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother 2008; 57: 1599–1609.

77. Fournier JJ, Sicard H, Poupot M, et al. What lessons can be learned from γδ T cell-based cancer immunotherapy trials? Cell Mol Immunol 2013; 10: 35–41.

78. Leslie DS, Vincent MS, Spada FM, et al. CD1-mediated γδ T cell maturation of dendritic cells. J Exp Med 2002; 196: 1575–1584.

79. Russano AM, Agea E, Corazzi L, et al. Recognition of polien-derived phosphatidyl-ethanolamine by human CD1d-restricted γδ T cells. J Allergy Clin Immunol 2006; 117: 1178–1184.

80. Spada FM, Grant EP, Peters PJ, et al. Self-recognition of CD1 by γδ T cells: implications for innate immunity. J Exp Med 2000; 191: 937–948.

81. Wu D, Wu P, Qiu F, et al. Human γδ T-cell subsets and their involvement in tumor immunity. Cell Mol Immunol 2017; 14: 245–253.

82. Wilcox CR, Pitard V, Netzer S, et al. Cytomegalovirus and tumor stress surveillance by binding of a human gd T cell antigen receptor to endothelial protein C receptor. Nat Immunol 2012; 9: 872–879.

83. Donia M, Ellebaek E, Andersen MH, et al. Analysis of Vα1 T cells in clinical grade melanoma-infiltrating lymphocytes. Oncoimmunology 2012; 1: 1297–1304.

84. Siegers GM, Dhamko H, Wang XH, et al. Human Vα1 γδ T cells expanded from peripheral blood exhibit specific cytotoxicity against B-cell chronic lymphocytic leukemia-derived cells. Cytotherapy 2011; 13: 753–764.

85. Lo Presti E, Dieli F, Meraviglia S. Tumor-infiltrating γδ T lymphocytes: pathogenic role, clinical significance, and differential programming in the tumor microenvironment. Front Immunol 2014; 5: 607.

86. Siegers GM, Lamb LS Jr. Cytotoxic and regulatory properties of circulating Vα1+ γδ T cells: a new player on the cell therapy field? Mol Ther 2014; 22: 1416–1422.

87. Fabre J, Giustini J, Garbar C, et al. Targeting the tumor microenvironment: the protumor effects of IL-17 related to cancer type. Int J Mol Sci 2016; 17: 1433.

88. Wakita D, Sumida K, Ikawara Y, et al. Tumor-infiltrating IL-17-producing γδ T cells support the progression of tumor by promoting angiogenesis. Eur J Immunol 2010; 40: 1927–1937.

89. Daley D, Zambirinis CP, Seifert L, et al. γδ T cells support pancreatic oncogenesis by restraining γδ T cell activation. Cell 2016; 166: 1485–1499 e1415.

90. Ma S, Cheng Q, Cai Y, et al. IL-17A produced by γδ T cells promotes tumor growth in hepatocellular carcinoma. Cancer Res 2014; 74: 1969–1982.

91. Van Hede D, Polese B, Humblet C, et al. Human papillomavirus oncoproteins induce a reorganization of epithelial-associated γδ T cells promoting tumor formation. Proc Natl Acad Sci USA 2017; 114: E9056–E9065.

92. Coffelt SB, Kersten K, Doornebal GW, et al. IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis. Nature 2015; 522: 345–348.

93. Jin C, Lagoudas GK, Zhao C, et al. Commensal microbiota promote lung cancer development via γδ T cells. Cell 2019; 176: 998–1013 e1016.

94. Giese M, Hind L, Hutfenlocher A. Neutrophil plasticity in the tumor microenvironment. Blood 2019; 133: 2159–2167.

95. Douguet L, Bod L, Labarthe L, et al. Inflammation drives nitric oxide synthase 2 expression by γδ T cells and affects the balance between melanoma and vitiligo associated melanoma. Oncoimmunology 2018; 7: e1484979.

96. McKenzie DR, Kara EE, Bastow CR, et al. IL-17-producing γδ T cells switch migratory patterns between resting and activated states. Nat Commun 2017; 8: 15632.

97. Lanca T, Costa MF, Goncalves-Sousa N, et al. Protective role of the inflammatory CCR88/CCL2 chemokine pathway through recruitment of type 1 cytotoxic γδ T lymphocytes to tumor beds. J Immunol 2013; 190: 6673–6680.

98. Kersten K, Coffelt SB, Hoogstraat M, et al. Mammary tumor-derived CCL2 enhances pro-metastatic systemic inflammation through upregulation of IL1β in tumor-associated macrophages. Oncoimmunology 2017; 6: e1334744.

99. Rubie C, Frick VO, Ghadjar P, et al. CCL20/CCR90 expression profile in pancreatic cancer. J Transl Med 2010; 8: 45.

100. Kapur N, Mir H, Clark lli CE, et al. CCR91 expression in colon cancer is associated with advanced disease and supports epithelial-to-mesenchymal transition. Br J Cancer 2016; 114: 1343–1351.

101. Mensurado S, Rei M, Lanca T, et al. Tumor-associated neutrophils suppress pro-tumoral IL-17+ γδ T cells through induction of oxidative stress. PLoS Biol 2018; 16: e2004990.

102. McAllister F, Bailey JM, Alsina J, et al. Oncogenic Kras activates a hematopoietic-to-epithelial IL-17 signaling axis in preinvasive pancreatic neoplasia. Cancer Cell 2014; 25: 621–637.

103. Zhang Y, Yan W, Collins MA, et al. Interleukin-6 is required for pancreatic cancer progression by promoting MAPK signaling activation and oxidative stress resistance. Cancer Res 2013; 73: 6359–6374.

104. Gunderson AJ, Kaneda MM, Tsujikawa T, et al. Bruton tyrosine kinase-dependent immune cell cross-talk drives pancreas cancer. Cancer Discov 2016; 6: 270–285.
105. Sharma P, Hu-Lieskovan S, Wargo JA, et al. Primary, adaptive, and acquired resistance to cancer immunotherapy. *Cell* 2017; 168: 707–723.

106. Martinez M, Moon EK. CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment. *Front Immunol* 2019; 10: 128.

107. Shah NN, Fry TJ. Mechanisms of resistance to CAR T cell therapy. *Nat Rev Clin Oncol* 2019; 16: 372–385.

108. Glienke W, Esser R, Priesner C, et al. Gamma delta T cells in human colorectal cancer. *Oncoimmunology* 2017; 6: e1284723.

109. Meraviglia S, Lo Presti E, Tosolini M, et al. Distinctive features of tumor-infiltrating γδ T lymphocytes in human colorectal cancer. *Oncoimmunology* 2017; 6: e1347742.

110. Thorsson V, Gibb DS, Brown SD, et al. The immune landscape of cancer. *Immunity* 2018; 48: 812–830 e814.

111. Siegers GM, Dutta I, Lai R, et al. Functional plasticity of gamma delta T cells and breast tumor targets in hypoxia. *Front Immunol* 2018; 9: 1367.

112. Di Lorenzo B, Simoes AE, Caiado F, et al. Broad cytotoxic targeting of acute myeloid leukemia by polyclonal delta one T cells. *Cancer Immunol Res* 2019; 7: 552–558.

113. Wu D, Wu P, Wu X, et al. Ex vivo expanded human circulating Vδ1 γδ T cells exhibit favorable therapeutic potential for colon cancer. *Oncoimmunology* 2015; 4: e992749.

114. Iwasaki M, Tanaka Y, Kobayashi H, et al. Expression and function of PD-1 in human γδ T cells that recognize phosphoantigens. *Eur J Immunol* 2011; 41: 345–355.

115. Brandes M, Willmann K, Moser B. Professional antigen-presentation function by human γδ T cells. *Science* 2005; 309: 264–268.

116. Shen Y, Zhou D, Qiu L, et al. Adaptive immune response of Vγ2Vδ2+ T cells during mycobacterial infections. *Science* 2002; 295: 2255–2258.

117. Pont F, Familiades J, Dejean S, et al. The gene expression profile of phosphoantigen-specific human γδ T lymphocytes is a blend of αβ T-cell and NK-cell signatures. *Eur J Immunol* 2012; 42: 228–240.

118. Hoeres T, Smetak M, Pretsch D, et al. Improving the efficiency of Vγ9Vδ2 T-cell immunotherapy in cancer. *Front Immunol* 2018; 9: 800.

119. Zou C, Zhao P, Xiao Z, et al. γδ T cells in cancer immunotherapy. *OncoTARGET* 2017; 8: 8900–8909.

120. Yu X, Harden K, Gonzalez LC, et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. *Nat Immunol* 2009; 10: 48–57.

121. Chan CJ, Martinet L, Gilfillan S, et al. The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions. *Nat Immunol* 2014; 15: 431–438.

122. Marin-Acevedo JA, Dholaria B, Soyano AE, et al. Next generation of immune checkpoint therapy in cancer: new developments and challenges. *J Hematol Oncol* 2018; 11: 39.

123. Capsomidis A, Benthall G, Van Acker HH, et al. Chimeric antigen receptor-engineered human gamma delta T cells: enhanced cytotoxicity with retention of cross presentation. *Mol Ther* 2018; 26: 354–365.

124. Pauza CD, Liou ML, Lahusen T, et al. Gamma delta T cell therapy for cancer: it is good to be local. *Front Immunol* 2018; 9: 1305.